Monitoring HPV vaccine impact: Early results and ongoing challenges

Journal of Infectious Diseases

Volumn 206, Issue 11, 2012, Pages 1633-1635

  Hariri, Susan ^a   Markowitz, Lauri ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

AUSTRALIA; CANCER PREVENTION; CONDYLOMA ACUMINATUM; EDITORIAL; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; PREVALENCE; PRIORITY JOURNAL; REGISTER; SELF REPORT; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; VACCINATION;

ALPHAPAPILLOMAVIRUS; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84869019086     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis593     Document Type: Editorial

References (13)

1. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012; 206:1645-51.
2. Wong CA, Saraiya M, Hariri S, et al. Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. Vaccine 2011; 29:878-85.
3. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010; 28:4731-7.
4. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85:499-502.
5. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39-44.
6. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87:544-7.
7. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012; 102:833-5.
8. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377:2085-92.
9. Agius PA, Pitts MK, Smith AM, Mitchell A. Human papillomavirus and cervical cancer: Gardasil vaccination status and knowledge amongst a nationally representative sample of Australian secondary school students. Vaccine 2010; 28:4416-22.
10. Weisberg E, Bateson D, McCaffery K, Skinner SR. HPV vaccination catch up program-utilisation by young Australian women. Aust Fam Physician 2009; 38:72-6.
11. Gertig DM, Brotherton JM, Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011; 8:171-8.
12. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199:926-35.
13. Kahn JA, Brown DR, Ding L, et al. Vaccinetype human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012; 130:e249-56.